Kawanishi C, Hanihara T, Shimoda Y, Suzuki K, Sugiyama N, Onishi H, Miyakawa T, Yamada Y, Kosaka K
Department of Psychiatry, Yokohama City University School of Medicine, Yokohama, Japan.
Am J Psychiatry. 1998 Sep;155(9):1275-7. doi: 10.1176/ajp.155.9.1275.
The molecular basis of neuroleptic malignant syndrome is unclear, but studies suggest that genetic factors are involved in its pathogenesis. Considering possible involvement of the serotonergic system in neuroleptic malignant syndrome, the authors examined the association between neuroleptic malignant syndrome and polymorphisms of the 5-HT1A and 5-HT2A receptor genes.
The authors examined the frequencies of gene polymorphisms in the 5-HT1A (Arg219Leu) and 5-HT2A (Thr25Asn and His452Tyr) receptor genes in 29 patients previously diagnosed with neuroleptic malignant syndrome, 94 neuroleptic-treated patients with schizophrenia who had no history of neuroleptic malignant syndrome, and 94 healthy comparison subjects. Polymerase chain reaction and restriction fragment length polymorphism analyses were used to screen gene mutations.
No polymorphic allele was detected in the patients who had experienced the neuroleptic malignant syndrome.
The authors cannot conclude that polymorphisms in the 5-HT1A and 5HT2A receptor genes are factors determining susceptibility to the neuroleptic malignant syndrome.
抗精神病药恶性综合征的分子基础尚不清楚，但研究表明遗传因素参与其发病机制。考虑到血清素能系统可能参与抗精神病药恶性综合征，作者研究了抗精神病药恶性综合征与5-HT1A和5-HT2A受体基因多态性之间的关联。
作者检测了29例先前诊断为抗精神病药恶性综合征的患者、94例接受抗精神病药治疗且无抗精神病药恶性综合征病史的精神分裂症患者以及94名健康对照者中5-HT1A（Arg219Leu）和5-HT2A（Thr25Asn和His452Tyr）受体基因的基因多态性频率。采用聚合酶链反应和限制性片段长度多态性分析来筛选基因突变。
在经历过抗精神病药恶性综合征的患者中未检测到多态性等位基因。
作者不能得出5-HT1A和5-HT2A受体基因多态性是决定抗精神病药恶性综合征易感性的因素这一结论。
